Breakthrough Targeted Therapy Successfully Treats Rare T-cell Lymphoma Post-CAR T Treatment

Researchers from The Tisch Cancer Institute at Mount Sinai have achieved a significant milestone by successfully treating a rare and aggressive T-cell lymphoma that developed after a patient received CAR T-cell therapy for multiple myeloma. This pioneering treatment marks the first documented case where targeted therapy was employed effectively against a CAR T-induced lymphoma. Published in the New England Journal of Medicine, the case involved a 51-year-old patient who initially went into complete remission from multiple myeloma following B-cell maturation antigen CAR T therapy. However, the patient later developed rapidly progressing T-cell lymphoma affecting his skin, blood, and bone marrow.

Using sophisticated genetic and immunological screening tools developed at Mount Sinai, the team identified a combination of FDA-approved drugs capable of targeting the lymphoma. A key discovery was the effectiveness of the anti-CCR4 antibody drug, which had not been previously used in this context. Administration of this drug led to remission from both the lymphoma and the original myeloma condition, showcasing the potential of precision medicine in managing complex cancer treatments.

Senior author Dr. Samir Parekh emphasized the significance of this development, stating, "This is the first reported case of successfully using targeted therapy to treat a CAR positive T-cell lymphoma. It underscores the importance of close monitoring for secondary cancers post-CAR T therapy and highlights how tailored treatments can respond swiftly to emerging complications."

This case contributes valuable insights into the understanding of rare side effects associated with CAR T-cell therapies and paves the way for developing safer, more durable treatment options for patients with multiple myeloma. Mount Sinai researchers continue to explore the biological mechanisms behind these rare occurrences and aim to enhance the safety profile of CAR T-cell treatments.

For more detailed information, see the study: Adolfo Aleman et al, 'Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy,' published in the New England Journal of Medicine (2025). Source: https://medicalxpress.com/news/2025-08-therapy-rare-cell-lymphoma-car.html